Literature DB >> 21602837

Association of serum omentin-1 levels with coronary artery disease.

Xia Zhong1, Hai-yang Zhang, Hui Tan, Yi Zhou, Fu-li Liu, Fu-qin Chen, De-ya Shang.   

Abstract

AIM: Omentin-1, a novel adipokine expressed in visceral adipose tissue, is negatively correlated with insulin resistance and obesity. Decreased omentin-1 expression has been found in many chronic inflammatory diseases. However, the role of omentin-1 in coronary artery disease (CAD) has not been elucidated. The aim of the present study was to determine whether serum concentration of omentin-1 was independently associated with CAD.
METHODS: One hundred and fifty five patients with CAD were divided into two groups: acute coronary syndrome (ACS) and stable angina pectoris (SAP). A total of 52 healthy participants served as controls. Serum concentrations of omentin-1 and interleukin-6 (IL-6) were measured using ELISA. The association of omentin-1 with CAD and cardiovascular disease risk factors was evaluated.
RESULTS: Serum omentin-1 levels were lower in patients with ACS or SAP compared with controls (ACS, 113.08±61.43 ng/mL; SAP, 155.41±66.89 ng/mL; control, 254.00±72.9 ng/mL; P<0.01). Patients with ACS also had lower serum concentrations of omentin-1 compared with patients with SAP (P<0.01). Serum concentration of omentin-1 was negatively correlated with body mass index (r=-0.17, P<0.05) and serum IL-6 concentration (r=-0.19, P<0.05). Furthermore, multiple logistic regression analysis showed that serum omentin-1 concentrations were independently correlated with CAD.
CONCLUSION: The findings suggest that serum concentrations of omentin-1 are related to CAD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21602837      PMCID: PMC4003121          DOI: 10.1038/aps.2011.26

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  33 in total

Review 1.  Adipocytokines: mediators linking adipose tissue, inflammation and immunity.

Authors:  Herbert Tilg; Alexander R Moschen
Journal:  Nat Rev Immunol       Date:  2006-09-22       Impact factor: 53.106

2.  Resistin and adiponectin levels in subjects with coronary artery disease and type 2 diabetes.

Authors:  Subhashini Yaturu; Robert P Daberry; Justin Rains; Sushil Jain
Journal:  Cytokine       Date:  2006-07-05       Impact factor: 3.861

3.  Adipokines and cardiometabolic function: How are they interlinked?

Authors:  Aletta Elisabeth Schutte; Hugo Willem Huisman; Rudolph Schutte; Johannes Marthinus van Rooyen; Leoné Malan; Catharina Maria Theresia Fourie; Nicolaas Theodore Malan
Journal:  Regul Pept       Date:  2010-07-06

4.  Omentin plasma levels and gene expression are decreased in obesity.

Authors:  Celia M de Souza Batista; Rong-Ze Yang; Mi-Jeong Lee; Nicole M Glynn; Dao-Zhan Yu; Jessica Pray; Kelechi Ndubuizu; Susheel Patil; Alan Schwartz; Mark Kligman; Susan K Fried; Da-Wei Gong; Alan R Shuldiner; Toni I Pollin; John C McLenithan
Journal:  Diabetes       Date:  2007-02-28       Impact factor: 9.461

5.  Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes.

Authors:  Susan Kralisch; Johannes Klein; Ulrike Lossner; Matthias Bluher; Ralf Paschke; Michael Stumvoll; Mathias Fasshauer
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-05-17       Impact factor: 4.310

6.  Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes.

Authors:  Hong-Yan Pan; Lin Guo; Qiang Li
Journal:  Diabetes Res Clin Pract       Date:  2010-02-02       Impact factor: 5.602

7.  Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action.

Authors:  Rong-Ze Yang; Mi-Jeong Lee; Hong Hu; Jessica Pray; Hai-Bin Wu; Barbara C Hansen; Alan R Shuldiner; Susan K Fried; John C McLenithan; Da-Wei Gong
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-03-10       Impact factor: 4.310

8.  Plasma concentrations of TNF-alpha and its soluble receptors sTNFR1 and sTNFR2 in patients with coronary artery disease.

Authors:  K Safranow; V Dziedziejko; R Rzeuski; E Czyzycka; A Wojtarowicz; A Bińczak-Kuleta; K Jakubowska; M Olszewska; A Ciechanowicz; Z Kornacewicz-Jach; B Machaliński; A Pawlik; D Chlubek
Journal:  Tissue Antigens       Date:  2009-11

9.  Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients.

Authors:  Young Keun On; Hyeong Kyu Park; Min Su Hyon; Eun-Seok Jeon
Journal:  Circ J       Date:  2007-06       Impact factor: 2.993

10.  Serum interleukin-6 levels, not genotype, correlate with coronary plaque complexity.

Authors:  Li-Tang Kuo; Ning-I Yang; Wen-Jin Cherng; Subodh Verma; Ming-Jui Hung; Shih-Yi Wang; Min-hui Liu; Shu-yi Chen; Chao-Hung Wang
Journal:  Int Heart J       Date:  2008-07       Impact factor: 1.862

View more
  31 in total

1.  New Biomarkers as Prognostic Factors for Cardiovascular Complications in Type 2 Diabetic Patients.

Authors:  Hanaa H Ahmed; Wafaa Gh Shousha; Hatem A El-Mezayen; Ibrahim A Emara; Marwa E Hassan
Journal:  Indian J Clin Biochem       Date:  2018-07-17

2.  Higher circulating omentin is associated with increased risk of primary cardiovascular events in individuals with diabetes.

Authors:  Corinna Niersmann; Maren Carstensen-Kirberg; Haifa Maalmi; Bernd Holleczek; Michael Roden; Hermann Brenner; Christian Herder; Ben Schöttker
Journal:  Diabetologia       Date:  2019-11-09       Impact factor: 10.122

Review 3.  Mechanisms linking adipose tissue inflammation to cardiac hypertrophy and fibrosis.

Authors:  Sarah R Anthony; Adrienne R Guarnieri; Anamarie Gozdiff; Robert N Helsley; Albert Phillip Owens; Michael Tranter
Journal:  Clin Sci (Lond)       Date:  2019-11-29       Impact factor: 6.124

Review 4.  Obesity-Induced Changes in Adipose Tissue Microenvironment and Their Impact on Cardiovascular Disease.

Authors:  José J Fuster; Noriyuki Ouchi; Noyan Gokce; Kenneth Walsh
Journal:  Circ Res       Date:  2016-05-27       Impact factor: 17.367

5.  Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism.

Authors:  Sonomi Maruyama; Rei Shibata; Ryosuke Kikuchi; Yasuhiro Izumiya; Taku Rokutanda; Satoshi Araki; Yoshiyuki Kataoka; Koji Ohashi; Hiroyuki Daida; Shinji Kihara; Hisao Ogawa; Toyoaki Murohara; Noriyuki Ouchi
Journal:  J Biol Chem       Date:  2011-11-11       Impact factor: 5.157

6.  Omentin inhibits the resistin-induced hypertrophy of H9c2 cardiomyoblasts by inhibiting the TLR4/MyD88/NF-κB signaling pathway.

Authors:  Xiaoliang Yan; Lin Wu; Min Gao; Pengjie Yang; Jinjing Yang; Yongzhi Deng
Journal:  Exp Ther Med       Date:  2022-02-17       Impact factor: 2.447

7.  The relation of omentin gene expression and glucose homeostasis of visceral and subcutaneous adipose tissues in non-diabetic adults.

Authors:  Afsoon Daneshafrooz; Emad Yuzbashian; Maryam Zarkesh; Golaleh Asghari; Parvin Mirmiran; Mehdi Hedayati; Raziyeh Abooshahab; S Melika Fanaei; Alireza Khalaj
Journal:  Mol Biol Rep       Date:  2021-11-05       Impact factor: 2.316

8.  Soluble intracellular adhesion molecule-1 and omentin-1 as potential biomarkers of subclinical atherosclerosis in hemodialysis patients.

Authors:  Marija Kocijancic; Zlatko Cubranic; Bozidar Vujicic; Sanjin Racki; Stefica Dvornik; Luka Zaputovic
Journal:  Int Urol Nephrol       Date:  2016-03-29       Impact factor: 2.370

9.  Association between continuous positive airway pressure and circulating omentin levels in patients with obstructive sleep apnoea.

Authors:  Firat Uygur; Hakan Tanrıverdi; Murat Can; Fatma Erboy; Bulent Altınsoy; Figen Atalay; Tacettin Ornek; Murat Damar; Furuzan Kokturk; Meltem Tor
Journal:  Sleep Breath       Date:  2016-01-25       Impact factor: 2.816

10.  Omentin-1 is decreased in maternal plasma, placenta and adipose tissue of women with pre-existing obesity.

Authors:  Gillian Barker; Ratana Lim; Harry M Georgiou; Martha Lappas
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.